NCT02810665 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I
New visual acuity charts for clinical research. Am J Ophthalmol. 1982 Jul;94(1):91-6.
Kaiser PK
Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc. 2009 Dec;107:311-24.
Ricci F, Cedrone C, Cerulli L
Standardized measurement of visual acuity. Ophthalmic Epidemiol. 1998 Mar;5(1):41-53. Review.
Ruamviboonsuk P, Tiensuwan M, Kunawut C, Masayaanon P
Repeatability of an automated Landolt C test, compared with the early treatment of diabetic retinopathy study (ETDRS) chart testing. Am J Ophthalmol. 2003 Oct;136(4):662-9.

Repeatability and Concordance of Visual Acuity Level Measured With ETDRS Numeric Charts, ETDRS Landolt C Charts, and Original ETDRS Letter Visual Acuity Charts in Thai Individuals

Details for clinical trial NCT02810665

Clinical trial NCT02810665 - References